Drug: Crizotinib (Xalkori, Pfizer)
Status:
- FDA has expanded the approved uses of crizotinib to include the treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have an ROS1 gene alteration (approximately 1% of patients with NSCLC).
- Crizotinib is the first and only FDA-approved treatment for patients with ROS1-positive NSCLC.
Significant Trial Data:
- Multicenter, single-arm trial in 50 patients aged 25 to 77 years with metastatic NSCLC